Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of fidaxomicin to preparation of product for inhibiting activity of mycobacterium abscessus

A technology of fidaxomicin and mycobacteria, applied in the field of medicine, can solve the problems that fidaxomicin has not yet inhibited mycobacterium abscessus

Pending Publication Date: 2022-03-25
BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +3
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] There is no report on the inhibition of Mycobacterium abscessus by fidaxomicin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of fidaxomicin to preparation of product for inhibiting activity of mycobacterium abscessus
  • Application of fidaxomicin to preparation of product for inhibiting activity of mycobacterium abscessus
  • Application of fidaxomicin to preparation of product for inhibiting activity of mycobacterium abscessus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Embodiment 1, Fidaxomycin is detected to the antibacterial activity of Mycobacterium abscessus standard strain

[0045] Drug to be tested: Fidaxomicin

[0046] 1. Add 100 μl of Mueller Hinton (MH) medium to each well of a 96-well plate;

[0047] 2. After completing step 1, take the 96-well plate and add 100 μl of the drug solution to be tested (prepared in DMSO) with a concentration of 128 μg / mL in the 12th column. After the second column, take out 100 μl and discard it, and the first column does not contain drug, which is the positive control well. Three replicate wells were set up for each concentration.

[0048] 3. After completing step 2, take the 96-well plate and add 100 μl of the bacterial suspension of Mycobacterium abscessus standard strain ATCC19977 to each well, so that the final volume in each well is 200 μl, and the final concentration of the bacterial solution is 2.5×10 5 CFU / mL; see Table 1 for the final drug concentration in each column well.

[0049...

Embodiment 2

[0060] Example 2, Fidaxomycin is detected for the antibacterial activity of clinically isolated Mycobacterium abscessus bacterial strains

[0061] Clinically isolated strains: 23 strains were isolated and cultured from sputum specimens of patients with Mycobacterium abscessus infection, and were identified as Mycobacterium abscessus by sequencing of 16SrRNA, hsp65, rpoB, and 16-23S rRNA region.

[0062] Drug to be tested: Fidaxomicin.

[0063] According to the method in Example 1, the bacteriostatic activity of the drug to be tested against 23 clinically isolated Mycobacterium abscessus strains was detected.

[0064] The MIC results are shown in Table 2. The statistical results of MIC concentration distribution are shown in Table 3 and figure 1 shown.

[0065] Table 2 Bacteriostatic activity of fidaxomicin to clinical isolates of Mycobacterium abscessus strains

[0066]

[0067]

[0068] Table 3 Statistical results of the MIC concentration distribution of fidaxomicin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of fidaxomicin to preparation of a product for inhibiting activity of mycobacterium abscessus. The invention provides application of fidaxomicin or a pharmaceutically acceptable salt thereof or a substance taking the fidaxomicin or the pharmaceutically acceptable salt thereof as an active ingredient in preparation of a product for inhibiting activity of mycobacterium abscessus. According to the invention, the anti-mycobacterium abscessus activity of fidaxomicin is determined by adopting a microwell plate double dilution method, and the result shows that fidaxomicin has better bacteriostatic activity on a mycobacterium abscessus standard strain and clinically separated mycobacterium abscessus; new application of fidaxomicin in prevention and treatment of mycobacterium abscessus infection diseases is expected to be explored.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a product for preparing fidaxomicin for inhibiting the activity of Mycobacterium abscessus. Background technique [0002] Non-tuberculous Mycobacteria (NTM) refers to mycobacteria other than Mycobacterium tuberculosis complex and Mycobacterium leprae. The characteristics of non-tuberculous mycobacteria are different from mycobacterium tuberculosis, such as being sensitive to acid and alkali; they are highly resistant to commonly used anti-tuberculosis drugs, such as isoniazid, rifampicin, streptomycin There are varying degrees of resistance to commonly used anti-tuberculosis drugs such as serotonin; the growth temperature is not as strict as that of Mycobacterium tuberculosis; it mostly exists in the environment; it is an opportunistic pathogen. In recent years, the infection caused by NTM has been on the rise gradually, posing a serious threat to human health. Therefore, it i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P31/04
CPCA61K31/7048A61P31/04
Inventor 王桂荣黄海荣李浩
Owner BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com